Immunotherapeutic Evaluation of Cancer Vaccines

Year 2018, Volume: 1 Issue: 1, 1 - 11, 30.12.2018

Burçin Erkal Ceyda Hayretdağ Örs Sevgi Kalkanlı Taş Nisa Begüm Erdoğan Arzum Şamlı Ender Coşkunpınar

Abstract

Tumor
vaccines which are among the methods of immunotherapy have an important place
against other treatment methods in the fight with cancer. The aim of
immunotherapy is to allow the cells of the immune system to destroy cancer
cells by targeting them. For this reason, 
commonly used immunotherapy methods include monoclonal antibodies, and
in particular cancer vaccines. In comparison to other methods, cancer vaccines
are more specific that activate T lymphocytes of patients and tries to
strengthen the defense of the organism against cancer cells. For this reason,
unlike other methods in the fight against cancer, cancer vaccination has been
used as a more specific treatment. Many new and effective cancer vaccines are likely
to arise with the advancement of studies. There are vaccines currently in
progress between phase II and III, which are pending approval from the Food and
Drug Administration (FDA). The progress of research on cancer vaccines and the
availability of new FDA-approved vaccines has been a source of hope for cancer
patients.

Keywords

Immunotherapy, cancer vaccine, monoclonal antibody

Kanser Aşılarının İmmünoterapötik Açıdan Değerlendirilmesi

Abstract

İmmünoterapi
yöntemleri arasında yer alan tümör aşıları, kanserle savaşta diğer tedavi
yöntemlerine karşı önemli bir yere sahiptir. İmmünoterapinin amacı, immün
sisteme ait hücrelerin kanser hücrelerini hedef alarak onları yok etmelerini
sağlamaktır. Bu sebeple en çok kullanılan immünoterapi yöntemlerinin arasında
monoklonal antikorlar ve özellikle de kanser aşıları yer almaktadır. Kanser
aşıları çok daha spesifik bir yöntem olup hastaların T lenfosit hücrelerini
aktive eder ve tümör hücrelerine karşı organizmanın savunmasını güçlendirmeye
çalışır. Bu sebeple, kanserle savaşta diğer yöntemlerin aksine daha özgün bir
tedavi olarak kullanılmaya başlanmıştır. Yapılan çalışmaların ileriye
taşınmasıyla birçok yeni ve etkili kanser aşılarının ortaya çıkması
muhtemeldir. Hali hazırda devam eden ve FDA’dan (Food and Drug
Administration)  onay almayı bekleyen faz
II ve III çalışmaları arasında yer alan aşılar bulunmaktadır. Kanser aşılarıyla
yapılan araştırmaların ilerlemesi ve FDA onaylı yeni aşıların bulunması kanser
hastaları için yeniden bir umut kaynağı olmuştur. 

Keywords

İmmünoterapi, kanser aşısı, monoklonal antikor

References

• Menaria, J., Kitawat, S. ve Verma, V. (2013). Cancer Vaccine: An Overview. Sch. J. App. Med. Sci., 1(3):161-171. Erişim adresi: https://pdfs.semanticscholar.org/7eb6/b0198a37ede3459a7894d97a6be4329d80a8.pdf Baykara, O. (2016). KANSER TEDAVİSİNDE GÜNCEL YAKLAŞIMLAR. Balikesir Saglik Bil Derg., 5:154-165. doi: 10.5505/bsbd.2016.93823. Praveen Kumar, V., Prasanthi, S., Lakshmi, V.R.S. ve Sai Santosh, M.V. (2010). Cancer Vaccines: A Promising Role in Cancer Therapy. Academic Journal of Cancer Research. 3 (2): 16-21. Erişim adresi: https://pdfs.semanticscholar.org/deef/86f0c852155714c3215ef6cbabadf27a953c.pdf Global Burden of Disease Cancer Collaboration, Fitzmaurice C ve diğerleri. (2018) Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. doi: 10.1001/jamaoncol.2018.2706. Özlük, A.A., Güner Oytun, M. ve Günenç, D. (2017). Kanser İmmünoterapisi. FNG & Bilim Tıp Transplantasyon Dergisi. 2(1):21-23. doi: 10.5606/fng.transplantasyon.2017.004 Melero, I., Gaudernack, G., Gerritsen, W. ve diğerleri. (2014). Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol. 11(9):509-24. Doi: 10.1038/nrclinonc.2014.111. Epub 2014 Jul 8. Şakalar, Ç., İzgi, K. ve Canatan H. (2013). Kanser İmmün Terapi ve Monoklonal Antikorlar. F.Ü.Sağ.Bil.Tıp Derg. 27 (2): 105 – 110. Erişim adresi: http://tip.fusabil.org/pdf/pdf_FUSABIL_929.pdf. Rayasam, S., Dudhgaonkar, S., Deshmukh, P., Sarda, S., Kinge, P. ve Hire, R. (2013) Monoclonal Antibodies in Therapeutics. Asian Journal of Biomedical and Pharmaceutical Sciences. 3(19), 35-39. Erişim adresi: https://www.alliedacademies.org/articles/monoclonal-antibodies-in-therapeutics.pdf Cai, H.H. (2018). Therapeutic monoclonal antibodies approved by FDA in 2017. MOJ Immunol. 6(3):82‒84. Erişim adresi: http://medcraveonline.com/MOJI/MOJI-06-00198.pdf Verma, S., Miles, D., Gianni, L., Krop, I.E., Welslau, M., Baselga, J. ve diğerleri. (2012). Trastuzumab emtansine for HER2- positive advanced breast cancer. N Engl J Med. 367:1783-91. DOI: 10.1056/NEJMoa1209124 Frank, M. ve Ihan A. (2006). Tumor vaccines. Radiol Oncol. 40(4): 219-29. Erişim adresi:https://www.onkoi.si/fileadmin/onko/datoteke/dokumenti/radiology_onkology_40_4_6.pdf Lollini, P.L., Cavallo, F., Nanni, P. ve Forni, G. (2006). Vaccines for tumour prevention. Nature Reviews Cancer. 6;204–216. Doi: 10.1038/nrc1815. Graziano, D.F. ve Finn, O.J. (2005). Tumor antigens and tumor antigen discovery. Cancer Treat Res. 123:89-111. Review. PubMed PMID: 16211867. Sheikhi, A., Jafarzadeh, A., Kokhaei, P. ve Hojjat-Farsangi, M. (2016). Whole Tumor Cell Vaccine Adjuvants: Comparing IL-12 to IL-2 and IL-15. Iran J Immunol. 13(3):148-66. doi: IJIv13i3A1. Review. PubMed PMID: 27671507. Delgado, I.E. (2002). Cancer Vaccines. The Oncologist. 7:20-33. doi: 10.1634/theoncologist.7-suppl_3-20. Palucka, K. ve Banchereau, J. (2013). Dendritic cell-based cancer therapeutic vaccines. Immunity. 39(1): 38–48. doi: 10.1016/j.immuni.2013.07.004. Sabado, R.L. ve Bhardwaj, N. (2015). Cancer immunotherapy: Dendritic-cell vaccines on the move. Nature. 300–301. doi: 10.1038/nature14211 Carralot, J.P., Weide, B. ve Schoor, O. ve diğerleri. (2005). Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas. Genet Vaccines Ther. 3: 6. doi: 10.1186/1479-0556-3-6. Scheel, B., Braedel, S. ve Probst, J. ve diğerleri. (2004). Immunostimulating capacities of stabilized RNA molecules. Eur J Immunol. 34(2):537-47. PubMed PMID: 14768059. DOI: 10.1002/eji.200324198. Guo, C., Manjili, M.H., Subjeck, J.R., Sarkar, D., Fisher, P.B. ve Wang X.Y. (2013). Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res. 119:421-75. doi:10.1016/B978-0-12-407190-2.00007-1. Review. PubMed PMID: 23870514; PubMed Central PMCID: PMC3721379. Emens, L.A. (2008). Cancer vaccines: on the threshold of success. Expert Opin Emerg Drugs. 13(2):295-308. doi: 10.1517/14728214.13.2.295 . Review. PubMed PMID: 18537522; PubMed Central PMCID: PMC3086397. Creative biolabs vaccine. Erişim tarihi: 27 Ağustos 2018. Erişim adresi: https://www.creative-biolabs.com/vaccine/anti-idiotype-vaccines.htm Immuno Oncology News. Erişim tarihi: 1 Eylül 2018. Erişim adresi: https://immuno-oncologynews.com/2018/07/03/aivita-launches-phase-2-trial-anti-cancer-vaccine-brain-cancer/ Güvenç, G., Akyüz, A. ve Seven M. (2012). Hemşirelik yüksek okulu öğrencilerinin human papilloma virüs enfeksiyonu ve aşıları ile ilgili bilgi ve tutumlarının belirlenmesi. Gülhane Tıp Derg. 54: 104-110. doi:10.5455/gulhane.18912. Aref-Adib, M. ve Freeman-Wang T. (2016). Cervical cancer prevention and screening: The role of human papillomavirus testing. The Obstetrician & Gynaecologist. 18:251–63. DOI: 10.1111/tog.12279. Aydoğdu, S.G.M. ve Özsoy, Ü. (2018). Serviks kanseri ve HPV. Androl Bul. 20:25−29 https://www.doi.org/10.24898/tandro.2018.62533. Tarassoff, C.P., Arlen, P.M. ve Gulley, J.L. (2006). Therapeutic vaccines for prostate cancer.Oncologist. 11(5):451-62. Review. PubMed PMID: 16720845. Cheever, M.A. ve Higano, C.S. (2011). PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res. 17(11):3520-6. doi: 10.1158/1078-0432.CCR-10-3126. Epub 2011 Apr 6. PubMed PMID: 21471425. Saavedra, D. ve Crombet, T. (2017). CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients. Front Immunol. 8:269. doi:10.3389/fimmu.2017.00269. eCollection 2017. Review. PubMed PMID: 28348561; PubMed Central PMCID: PMC5346887. Rodríguez, P.C., Rodríguez, G., González, G. ve Lage, A. (2010). Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy. MEDICC Rev. 12(1):17-23. Review. PubMed PMID: 20387330. Pérez, A., Dickinson, F., Cinza, Z. ve diğerleri. (2001) Safety and preliminary immunogenicity of the recombinant outer membrane protein P64k of Neisseria meningitidis in human volunteers. Biotechnol Appl Biochem. 34(Pt2):121-5. PubMed PMID: 11592918. Rodriguez, P.C., Popa, X. ve diğerleri. (2016). A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients. Clin Cancer Res. 22(15):3782-90. doi: 10.1158/1078-0432.CCR-15-0855. Epub 2016 Feb 29. PubMed PMID: 26927662. Maciejko, L., Smalley, M. ve Goldman, A. (2017) Cancer Immunotherapy and Personalized Medicine: Emerging Technologies and Biomarker-Based Approaches. J Mol Biomark Diagn. 8(5): 350. doi: 10.4172/2155-9929.1000350.